Therefore, our study aimed to explore the regulatory factors and mechanisms of KRAS mutant LUAD from the perspective of blocking the Ras signaling pathway and antagonizing relevant influencing molecules, explore new therapeutic targets and provide new guidance for targeted tumor therapies. The gene discussed is KRAS; the disease is neoplasm.